Page last updated: 2024-11-12
sk&f 107647
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
SK&F 107647: a synthetic hematoregulatory peptide that shares biological and/or modulatory activities with natural hematopoetic cytokines [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 9898394 |
| CHEMBL ID | 412415 |
| SCHEMBL ID | 609834 |
| MeSH ID | M0228151 |
Synonyms (20)
| Synonym |
|---|
| sb-107647 |
| skf-107647 |
| glaspimod |
| CHEMBL412415 |
| sk&f 107647 |
| n(sup 2),n(sup 2)'-((2s,7s)-2,7-bis((2s)-3-carboxy-2-((2s)-4-carboxy-2-((2s)-5-oxo-2-pyrrolidinecarboxamido)butyramido)propionamido)octanedioyl)di-l-lysine |
| glaspimod [inn:ban] |
| (s)-5-oxo-l-prolyl-l-alpha-glutamyl-l-alpha-aspartyl-n8-(5-amino-1-carboxypentyl)-8-oxo-n7-(n-(n-(5-oxo-l-prolyl)-l-alpha-glutamyl)-l-alpha-aspartyl)-2,7,8-triaminooctanoyl-l-lysine |
| unii-198e564v9f |
| sk&f-107647 |
| 198e564v9f , |
| l-lysine, 5-oxo-l-prolyl-l-alpha-glutamyl-l-alpha-aspartyl-n8-(5-amino-1-carboxypentyl)-8-oxo-n7-(n-(n-(5-oxo-l-prolyl)-l-alpha-glutamyl)-l-alpha-aspartyl)-2,7,8-triaminooctanoyl-, (s)- |
| 134143-28-5 |
| SCHEMBL609834 |
| glaspimod [inn] |
| l-lysine, n2,n7-bis(5-oxo-l-prolyl-l-.alpha.-glutamyl-l-.alpha.-aspartyl)-(2s,7s)-2,7-diaminooctanedioylbis- |
| (2s)-6-amino-2-[[(2s,7s)-8-[[(1s)-5-amino-1-carboxypentyl]amino]-2,7-bis[[(2s)-3-carboxy-2-[[(2s)-4-carboxy-2-[[(2s)-5-oxopyrrolidine-2-carbonyl]amino]butanoyl]amino]propanoyl]amino]-8-oxooctanoyl]amino]hexanoic acid |
| Q27252083 |
| (4s,7s,10s,15s,18s,21s)-10,15-bis(((s)-5-amino-1-carboxypentyl)carbamoyl)-7,18-bis(carboxymethyl)-5,8,17,20-tetraoxo-4,21-bis((s)-5-oxopyrrolidine-2-carboxamido)-6,9,16,19-tetraazatetracosanedioic acid |
| AKOS040746858 |
Research Excerpts
Pharmacokinetics
| Excerpt | Reference | Relevance |
|---|---|---|
| "W(b)), body-weight normalized human pharmacokinetic data were reasonably predicted using either the body weight normalized rat or the dog data." | ( Interspecies pharmacokinetics of a novel hematoregulatory peptide (SK&F 107647) in rats, dogs, and oncologic patients. Boppana, V; Brocks, DR; Citerone, DR; Davies, BE; Freed, MI; Jorkasky, DK; Levitt, B; Martin, DE; Mehdi, N; Nemunaitis, J; Sellers, TS, 1996) | 0.53 |
Compound-Compound Interactions
| Excerpt | Reference | Relevance |
|---|---|---|
| " However, when SK&F 107647 was administered in combination with low doses of amphotericin B, there was a significant reduction in organism burden in the lungs, liver, spleen, and kidneys compared with the burdens in the organs of untreated control animals and in the lungs and kidneys compared with the burdens in the lungs and kidneys of animals treated with amphotericin B alone." | ( Effects of the hematoregulatory peptide SK&F 107647 alone and in combination with amphotericin B against disseminated candidiasis in persistently neutropenic rabbits. Gonzalez, C; Lee, J; Lyman, CA; Schneider, M; Walsh, TJ, 1999) | 0.92 |
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| " Additionally, significant increases in survival in non-irradiated immunocompetent mice dosed by oral gavage were observed." | ( Efficacy of the hematoregulatory peptide SK&F 107647 in experimental systemic Candida albicans infections in normal and immunosuppressed mice. Actor, P; Bhatnagar, PK; DeMarsh, PL; Frey, CL; Koltin, Y; Petteway, SR; Sucoloski, SK, ) | 0.4 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (6)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID44633 | Neutralization of colony - stimulating activity was determined by incubating supernatants from stromal cells stimulated by compound (1000 ng/mL) with an antibody raised against KC[38-72]. | 1997 | Journal of medicinal chemistry, Aug-29, Volume: 40, Issue:18 | Design of low molecular weight hematoregulatory agents from the structure-activity relationship of a dimeric pentapeptide. |
| AID225220 | In vitro ability to induce a hematopoietic synergistic factor from a murine stromal cell line at 10.0 ug/mL | 2000 | Bioorganic & medicinal chemistry letters, Mar-20, Volume: 10, Issue:6 | Novel peptidomimetic hematoregulatory compounds. |
| AID225217 | In vitro ability to induce a hematopoietic synergistic factor from a murine stromal cell line at 0.10 ug/mL | 2000 | Bioorganic & medicinal chemistry letters, Mar-20, Volume: 10, Issue:6 | Novel peptidomimetic hematoregulatory compounds. |
| AID225219 | In vitro ability to induce a hematopoietic synergistic factor from a murine stromal cell line at 1.0 ug/mL | 2000 | Bioorganic & medicinal chemistry letters, Mar-20, Volume: 10, Issue:6 | Novel peptidomimetic hematoregulatory compounds. |
| AID44630 | Relative potency for induction of Colony-Stimulating activity(CSA) of C6 stromal line. | 1996 | Journal of medicinal chemistry, Sep-13, Volume: 39, Issue:19 | Structure-activity relationships of novel hematoregulatory peptides. |
| AID44634 | HSF produced by bone marrow-derived stromal cell lines C6.4 on stimulation with the compound at (1000 ng/mL) was determined in vitro in an GM-CFC assay. | 1997 | Journal of medicinal chemistry, Aug-29, Volume: 40, Issue:18 | Design of low molecular weight hematoregulatory agents from the structure-activity relationship of a dimeric pentapeptide. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (14)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 11 (78.57) | 18.2507 |
| 2000's | 3 (21.43) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 11.62
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.62) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (6.67%) | 5.53% |
| Reviews | 2 (13.33%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 12 (80.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||